Latest & greatest articles for corticosteroids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on corticosteroids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on corticosteroids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for corticosteroids

106. Inhaled corticosteroids for acute asthma in adults and adolescents

Inhaled corticosteroids for acute asthma in adults and adolescents

DynaMed Plus2017

112. Systemic corticosteroids for acute asthma in adults and adolescents

Systemic corticosteroids for acute asthma in adults and adolescents

DynaMed Plus2017

113. Antenatal corticosteroid administration between 24 hours and 7 days before extremely preterm delivery is associated with the lowest rate of mortality

Antenatal corticosteroid administration between 24 hours and 7 days before extremely preterm delivery is associated with the lowest rate of mortality Antenatal corticosteroid administration between 24 hours and 7 days before extremely preterm delivery is associated with the lowest rate of mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Antenatal corticosteroid administration between 24 hours and 7 days before extremely

Evidence-Based Medicine (Requires free registration)2017

114. In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids | BMJ Evidence-Based Medicine We use cookies to improve our service (...) name or password? You are here In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids Article Text Commentary General medicine In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

Evidence-Based Medicine (Requires free registration)2017

115. CORTIMENT (budesonide), corticosteroid for local use

CORTIMENT (budesonide), corticosteroid for local use Haute Autorité de Santé - CORTIMENT (budésonide), corticoïde d’action locale Contribuer à la régulation par la qualité et l'efficience Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments CORTIMENT (budésonide), corticoïde d’action locale Substance active (DCI) budésonide GASTRO-ENTEROLOGIE - Nouveau médicament Nature de la demande Inscription Avis de la CT du 25

Haute Autorite de sante2017

116. Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects

Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects - GOV.UK GOV.UK uses cookies to make the site simpler. Search Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects From: Published: 14 December 2016 Therapeutic area: , , , , , , and Coadministration of a corticosteroid with an HIV (...) -treatment-boosting agent may increase the risk of adrenal suppression due to a pharmacokinetic interaction. Contents Advice for healthcare professionals: all clinicians who may prescribe or administer steroids to patients with HIV should be aware that concomitant use of a corticosteroid metabolised by cytochrome P450 3A (CYP3A) and a HIV-treatment-boosting agent may increase the risk of systemic corticosteroid-related adverse effects although these reactions are rarely reported, there is potential

MHRA Drug Safety Update2017

117. Intra-articular Corticosteroids for Osteoarthritis of the Knee.

Intra-articular Corticosteroids for Osteoarthritis of the Knee. Clinical Question: Are intra-articular corticosteroids associated with improvement in pain and physical function compared with sham injection or no intervention in patients with knee osteoarthritis? Bottom Line: Intra-articular corticosteroids may be associated with moderate improvement in pain and a small improvement in physical function up to 6 weeks after injection. However, the quality of the evidence is low.

JAMA2016 Full Text: Link to full Text with Trip Pro

118. Juvenile X-linked retinoschisis responsive to intravitreal corticosteroids

Juvenile X-linked retinoschisis responsive to intravitreal corticosteroids 29503947 2018 11 14 2451-9936 5 2017 Apr American journal of ophthalmology case reports Am J Ophthalmol Case Rep Juvenile X-linked retinoschisis responsive to intravitreal corticosteroids. 48-51 10.1016/j.ajoc.2016.12.002 To report the case of an adult male with X-linked retinoschisis (XLRS) who presented with cystoid macular edema (CME) that responded consistently to treatment with intravitreal steroids. A 39 year old (...) recurrences in 3 month intervals for 5 additional injections. Finally, an intravitreal fluocinolone acetonide implant was surgically placed with control of CME. Corticosteroids have never been reported to be effective in CME related to XLRS. Here, we document a case of a man who successfully had decrease of intraretinal fluid and schisis with treatment of intravitreal corticosteroids as demonstrated by spectral domain optical coherence tomography. Ansari Waseem H WH Cleveland Clinic Foundation, Cole Eye

American journal of ophthalmology case reports2016 Full Text: Link to full Text with Trip Pro

119. Do corticosteroid injections improve carpal tunnel syndrome symptoms?

Do corticosteroid injections improve carpal tunnel syndrome symptoms? Do corticosteroid injections improve carpal tunnel syndrome symptoms? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do corticosteroid injections improve carpal tunnel syndrome symptoms? View/ Open Date 2016-02 Format Metadata Abstract Q: Do (...) corticosteroid injections improve carpal tunnel syndrome symptoms? Evidence-based answer: Yes. injected corticosteroids reduce symptoms of carpal tunnel syndrome (CTS) more effectively than placebo or systemic steroids, but no better than anti-inflammatory medication and splinting, from one to 12 weeks after therapy (strength of recommendation [SOR]: A, meta-analysis of randomized controlled trials [RCTs] and consistent RCT). A 40-mg injection of methylprednisolone reduces symptoms as effectively as an 80-mg

Clinical Inquiries2016

120. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study.

Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. BACKGROUND: Low-dose inhaled corticosteroids (ICS) are highly effective for reducing asthma exacerbations and mortality. Conventionally, ICS treatment is recommended for patients with symptoms on more than 2 days per week, but this criterion has scant evidence. We aimed to assess the validity of the previous symptom-based cutoff (...) regular corticosteroids were randomised to receive once daily, inhaled budesonide 400 μg (those aged <11 years 200 μg) or placebo. Coprimary outcomes for this analysis were time to first severe asthma-related event (SARE; hospital admission, emergency treatment, or death) and change from baseline in lung function after bronchodilator. Interaction with baseline symptom frequency was investigated, with patients grouped by more than two symptom days per week and two or fewer symptom days per week

Lancet2016